Revenue
2022
2023
2024
2025
Prelude Therapeutics Inc (PRLD)
Price$5.46Cached quote
Net income
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $12.1M | $7.0M | $0 | $0 | — | — | — |
| Research & development | $94.3M | $118.0M | $103.4M | $92.9M | $86.8M | $48.2M | $24.3M |
| Operating expenses | $116.7M | $146.7M | $132.3M | $123.5M | $113.7M | $58.8M | $28.1M |
| Operating income | −$104.6M | −$139.7M | −$132.3M | −$123.5M | −$113.7M | −$58.8M | −$28.1M |
| Operating margin | −861.33% | −1,995.91% | — | — | — | — | — |
| EBITDA | −$102.9M | −$137.9M | −$131.1M | −$122.2M | −$112.8M | −$58.2M | −$27.7M |
| EBITDA margin | −847.24% | −1,970.60% | — | — | — | — | — |
| Net income | −$99.5M | −$127.2M | −$121.8M | −$115.4M | −$111.7M | −$56.9M | −$27.6M |
| Net profit margin | −819.59% | −1,816.76% | — | — | — | — | — |
| Basic EPSper basic share | -$1.29 | -$1.68 | -$2.02 | -$2.44 | -$2.43 | -$4.56 | -$16.52 |
| Diluted EPSper diluted share | -$1.29 | -$1.68 | -$2.02 | -$2.44 | -$2.43 | -$4.56 | -$16.52 |
Owners
Reported shareholders
Reported holdings Number of shares
View holders
| Holder | Shares held |
|---|---|
ORBIMED ADVISORS LLC | 13.72M |
Bonita David P | 13.46M |
BAKER BROS. ADVISORS LP | 10.12M |
RA CAPITAL MANAGEMENT, L.P. | 6.48M |
Soleus Capital Management, L.P. | 3.38M |
Kynam Capital Management, LP | 2.42M |
VANGUARD CAPITAL MANAGEMENT LLC | 2.01M |
BlackRock, Inc. | 1.8M |
SPHERA FUNDS MANAGEMENT LTD. | 1.02M |
TWO SIGMA INVESTMENTS, LP | 993.37K |
ADAR1 Capital Management, LLC | 900.9K |
MILLENNIUM MANAGEMENT LLC | 844.99K |
GEODE CAPITAL MANAGEMENT, LLC | 841.86K |
ADAGE CAPITAL PARTNERS GP, L.L.C. | 766.1K |
ACADIAN ASSET MANAGEMENT LLC | 611.36K |
MORGAN STANLEY | 503.86K |
Combs Andrew | 480.12K |
STATE STREET CORP | 428.79K |
UBS Group AG | 318.8K |
VANGUARD FIDUCIARY TRUST CO | 284.89K |
Bars compare reported share counts. A matching total for this share class and reporting period is unavailable, so percentages are not shown.
Source: SEC Form 13F ↗Updated Sep 29, 2026 · Quarterly data
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Apr 21, 2026Form 4 | Bonita David PDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.13M | $4.44 | $5.00M | 1.13M |
| Apr 21, 2026Form 4 | Bonita David PDirector,TenPercentOwner | BuyCommon Stock · indirect | 1.69M | $4.44 | $7.50M | 11.81M |
| Apr 21, 2026Form 4 | OrbiMed Genesis GP LLC +3Director,TenPercentOwner | BuyCommon Stock · indirect | 1.13M | $4.44 | $5.00M | 1.13M |
| Apr 21, 2026Form 4 | OrbiMed Genesis GP LLC +3Director,TenPercentOwner | BuyCommon Stock · indirect | 1.69M | $4.44 | $7.50M | 11.81M |
| Apr 21, 2026Form 4 | 667, L.P. +5Director,TenPercentOwner | BuyWarrants to purchase Common Stock · derivative · indirect | 2.14M | $4.44 | $9.49M | 20.11M |
Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...
